Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of Priorix-Tetra lots using new versus old measles and rubella working seeds in healthy children
2011-005881-38Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK208136 in measles, mumps, rubella and 1 more (2 arms), sponsored by GSK. Primary endpoints: Seroconversion rate for measles after dose 1, Seroconversion rate for mumps after dose 1 and 2 more.
02
Drugs
GSK208136
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2011-005881-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005881-38.